Fundraising Fox
Prexton Therapeutics
acquired by LundbeckCopenhagen, DK · Founded 1915 · 6,027 employees on LinkedIn · 6 known investors
Find your way into Prexton Therapeutics
Sign up to find every way you can get introduced to Prexton Therapeutics
- Your email: who you already know at Prexton Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Prexton Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Prexton Therapeutics was a biopharmaceutical company developing novel therapies for Parkinson's disease, including its lead mGluR4 modulator candidate foliglurax. Acquired by Lundbeck in 2018.
Investors · 6
How we know: Cardinal Partners's portfolio page · Not right? Tell us
How we know: M Ventures's portfolio page · Not right? Tell us
How we know: Seroba Life Sciences's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: Sunstone Capital's portfolio page · funding news · the VCSheet dataset · Not right? Tell us
How we know: Ysios Capital's portfolio page · funding news · the VCSheet dataset · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Related companies · 1
Companies working in the same space as Prexton Therapeutics.
Frequently asked questions
- What does Prexton Therapeutics do?
- Prexton Therapeutics was a biopharmaceutical company developing novel therapies for Parkinson's disease, including its lead mGluR4 modulator candidate foliglurax. Acquired by Lundbeck in 2018.
- Who are Prexton Therapeutics's investors?
- Prexton Therapeutics's investors include Cardinal Partners, M Ventures, Seroba Life Sciences, Sunstone Capital, Ysios Capital, Forbion.
- Who acquired Prexton Therapeutics?
- Prexton Therapeutics was acquired by Lundbeck.
- Where is Prexton Therapeutics headquartered?
- Prexton Therapeutics is headquartered in Copenhagen, DK.